[1] Mena-Durán A, Muoz Vicente E, Pareja Llorens G, et al. Liver failure caused by light chain deposition disease associated with multiple myeloma. Japan J Med, 2012, 51: 773-776.
[2] Mateos MV, Richardson PG, Schlag R, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol, 2010, 28: 2259-2266.
[3] 沈恺妮, 李剑. 原发性轻链型淀粉样变的治疗进展. 中国实验血液学杂志, 2015, 23: 910-914.
[4] Mikhael JR, Schuster SR, Jimenez-Zepeda VH, et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood, 2012, 119: 4391-4394. |
